Cold & Flu Drugs - Global Market Outlook (2018-2027)

According to Stratistics MRC, the Global Cold & Flu Drugs Market is accounted for $12.78 billion in 2018 and is expected to reach $26.40 billion by 2027 growing at a CAGR of 8.4% during the forecast period.  Some of the key factors propelling the market growth include increasing cases of obesity all over the globe, increasing binge eating and consumption of junk foods, neglect towards regular exercise, rising levels of stress. However, cold & flu drugs may causes allergic reaction is likely to hamper the market.

Cold and Flu is a most common diseases infect to human. People think cold and flu is not major but sometimes it may be harmful for those. Due this awareness Cold and Flu Drugs is on demand. Cold and Flu Drugs are easily available in any medical store and less expense.

By application, over the counter (OTC) drugs segment is poised to witness lucrative growth over the forecast timeframe, due to increasing prevalence of digestion disorders, common flu, and cold. Over-the-counter (OTC) drugs also called as non-prescription drugs are medicines that do not require prescription from healthcare professionals for selling it to consumers. These drugs are available at pharmacies, supermarkets, general stores, and gas stations across several countries. However, these drugs are solely authorized for dispense by pharmacists, after confirming age, identity, and patient’s knowledge regarding the product and its utility.

On the basis of geography, Asia Pacific region is projected to have considerable market growh during the forecast period, owing to growing patient awareness regarding consumption of OTC drugs, leading to self-medication practices. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades.

Some of the key players in cold & flu drugs market include Bayer, AstraZeneca, Procter and Gamble, Reckitt Benckiser Group, Johnson & Johnson, GlaxoSmithKline, Novartis, Sun Pharmaceutical Industries, Pfizer, and Prestige Brands Holdings.

Product Types Covered:
• Decongestants
• Antibiotics
• Antihistamines
• Expectorants
• Bronchodilators

Applications Covered:
• Rx Drugs
• Over the Counter (OTC) Drugs

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK 
o Spain
o Rest of Europe      
• Asia Pacific
o Japan       
o China       
o India       
o Australia       
o New Zealand      
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2017, 2018, 2019, 2023 and 2027
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter’s five forces analysis, SWOT analysis, etc.
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances